Mission
At Wholomics we are developing a novel multi-cancer detection liquid biopsy that is quick, easy, and more accurate than any other screening test on the market. Our tests are designed to detect the presence of cancer-specific molecular signatures in the blood, allowing early detection of a multitude of cancer types. With our novel multi-omics approach we bring state-of-the-art technologies in combination with AI straight to the patients.
“If the blind study confirms your previous results, everybody will use your test!”
— Gastrointestinal Oncologists - Top 3 Cancer Institute Worldwide
Our Mission
Our mission is to detect cancer early and improve the chances of survival. We develop accurate and minimally-invasive cancer screening tests and strive to make them accessible and affordable by incorporating them into a daily clinical basis. We are dedicated to helping people take control of their health, make live easier, and give them a chance to beat cancer.
“This novel technique will change the cancer diagnosis field with a big bang.”
— Scientist - Subject Matter Expert
What We’ve Achieved
Diagnosed pancreatic cancer at Stage I with groundbreaking precision.
Presented successful pilot study at ASCO GI Symposium 2024 in San Francisco.
Revealed our successful blinded validation study at ASCO Annual Meeting 2024 in Chicago.
Got accepted into the world-renowned Mass Challenge accelerator.
Demonstrated very high detection accuracy for multiple cancer types.
“If this comes, everybody will be interested in it.”
— Pancreatic Cancer Oncologists - Top 10 worldwide